0000320335-22-000028.txt : 20221026 0000320335-22-000028.hdr.sgml : 20221026 20221026163142 ACCESSION NUMBER: 0000320335-22-000028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221026 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221026 DATE AS OF CHANGE: 20221026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GLOBE LIFE INC. CENTRAL INDEX KEY: 0000320335 STANDARD INDUSTRIAL CLASSIFICATION: LIFE INSURANCE [6311] IRS NUMBER: 630780404 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08052 FILM NUMBER: 221333617 BUSINESS ADDRESS: STREET 1: 3700 SOUTH STONEBRIDGE DRIVE CITY: MCKINNEY STATE: TX ZIP: 75070 BUSINESS PHONE: 972-569-4000 MAIL ADDRESS: STREET 1: 3700 SOUTH STONEBRIDGE DRIVE CITY: MCKINNEY STATE: TX ZIP: 75070 FORMER COMPANY: FORMER CONFORMED NAME: TORCHMARK CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TORCHMARK CORP SAVINGS & INVESTMENT PLAN DATE OF NAME CHANGE: 19820825 FORMER COMPANY: FORMER CONFORMED NAME: LIBERTY NATIONAL INSURANCE HOLDING CO DATE OF NAME CHANGE: 19820701 8-K 1 gl-20221026.htm 8-K (Q3 2022 EARNINGS RELEASE) gl-20221026
0000320335false00003203352022-10-262022-10-260000320335us-gaap:CommonStockMember2022-10-262022-10-260000320335us-gaap:SubordinatedDebtMember2022-10-262022-10-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2022
GLOBE LIFE INC.
(Exact name of registrant as specified in its charter)
Delaware 001-0805263-0780404
(State or other jurisdiction
of incorporation)
 
(Commission
File No.)
(I.R.S. Employer
ID No.)
3700 South Stonebridge Drive, McKinney, Texas 75070
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (972569-4000
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a.-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par value per shareGLNew York Stock Exchange
4.250% Junior Subordinated DebenturesGL PRDNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02    Results of Operations and Financial Condition.
On October 26, 2022, Globe Life Inc. issued a press release announcing its third quarter 2022 financial results. A copy of the press release is incorporated herein by reference and is provided as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information included or incorporated in this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be set forth by specific reference in such filing.
Item 9.01    Financial Statement and Exhibits.
(a)Financial Statements of businesses or funds acquired.
Not applicable.
(b)Pro forma financial information.
Not applicable.
(c)Shell company transactions.
Not applicable
(d)Exhibits.
(104) Cover Page Interactive Data File (embedded within the Inline XBRL document)






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: October 26, 2022
 GLOBE LIFE INC.
 /s/ Christopher T. Moore
 Christopher T. Moore

Corporate Senior Vice President,
Associate Counsel and Corporate Secretary


EX-99.1 2 q3fy2022earningsrelease.htm EX-99.1 Document

globelifeheader.gif

GLOBE LIFE INC. REPORTS
Third Quarter 2022 Results


McKinney, TX, October 26, 2022—Globe Life Inc. (NYSE: GL) reported today that for the quarter ended September 30, 2022, net income was $1.90 per diluted common share, compared with $1.84 per diluted common share for the year-ago quarter. Net operating income for the quarter was $2.15 per diluted common share, compared with $1.78 per diluted common share for the year-ago quarter.


HIGHLIGHTS:
l
Net income as an ROE was 11.2% for the nine months ended September 30, 2022. Net operating income as an ROE excluding net unrealized gains or losses on fixed maturities was 13.1% for the same period.
l
Life premiums increased 6% at the American Income Life Division and 5% at the Liberty National Division over the year-ago quarter.
l
Total health premiums increased over the year-ago quarter by 7%.
l
Total health net sales increased 10% over the year-ago quarter.
l
563,574 shares of Globe Life Inc. common stock were repurchased during the quarter.


COVID-19 Update: COVID life claims expense for the quarter ended September 30, 2022 was not significant, compared to $33 million in the quarter ended September 30, 2021. Year to date through September 30, we incurred $44 million of COVID life claims as compared to $82 million for the same period last year. For the full year, we expect to incur approximately $51 million of COVID life claims at the midpoint of our guidance, based on a range of $1.9 million to $2.1 million of COVID life claims per 10,000 U.S. deaths and total U.S. COVID deaths of 240,000 to 260,000. For 2023, at the midpoint of our guidance, we anticipate total COVID life claims of approximately $20 million based on estimated total U.S. deaths of approximately 105,000.










Note: As used in the earnings release, "Globe Life," the "Company," "we," "our," and "us" refer to Globe Life Inc., a Delaware corporation incorporated in 1979, its subsidiaries and affiliates.
1
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
RESULTS OF OPERATIONS

Net operating income, a non-GAAP(1) financial measure, has been used consistently by Globe Life’s management for many years to evaluate the operating performance of the Company, and is a measure commonly used in the life insurance industry. It differs from net income primarily because it excludes certain non-operating items such as realized investment gains and losses and certain significant and unusual items included in net income. Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company’s business. Net income is the most directly comparable GAAP measure.

The following table represents Globe Life's operating summary for the three months ended September 30, 2022 and 2021:
Operating Summary
Per Share
Three Months Ended
September 30,
Three Months Ended
September 30,
20222021%
Chg.
20222021%
Chg.
Insurance underwriting income(2)
$2.20 $1.69 30$215,803 $173,435 24
Excess investment income(2)
0.57 0.58 (2)56,427 59,234 (5)
Parent company expense(0.03)(0.02)(2,556)(2,176)
Income tax expense(0.53)(0.42)26(52,160)(43,258)21
Stock compensation benefit (expense), net of tax(0.07)(0.05)(6,583)(4,745)
Net operating income 2.15 1.78 21210,931 182,490 16
Reconciling items, net of tax:
Realized gain (loss)—investments(0.23)0.15 (23,033)15,633 
Realized gain (loss)—redemption of debt— (0.07)— (7,358)
Non-operating expenses— (0.02)— (1,894)
Legal proceedings(0.01)— (1,119)— 
Net income(3)
$1.90 $1.84 $186,779 $188,871 
Weighted average diluted shares outstanding 98,148 102,381 
(1)GAAP is defined as accounting principles generally accepted in the United States of America.
(2)Definitions included within this document.
(3)A GAAP-basis condensed consolidated statement of operations is included in the appendix of this report.


Note: Tables in this earnings release may not sum due to rounding.




2
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
MANAGEMENT VS. GAAP MEASURES

Shareholders' equity, excluding net unrealized gains or losses on fixed maturities, and book value per share, excluding net unrealized gains or losses on fixed maturities, are non-GAAP measures that are utilized by management to view the business without the effect of unrealized gains or losses which are primarily attributable to fluctuation in interest rates associated with the available-for-sale portfolio. Management views the business in this manner because the Company does not intend to sell, nor is it likely that management will be required to sell, the fixed maturities prior to their maturity. It also creates more meaningful and easily identifiable trends, as we exclude fluctuations resulting from changes in interest rates. Shareholders' equity and book value per share are the most directly comparable GAAP measures.
Nine Months Ended
September 30,
20222021
Net income as an ROE(1)
11.2 %8.9 %
Net operating income as an ROE (excluding net unrealized gains or losses on fixed maturities)
13.1 %12.5 %
September 30,
20222021
Shareholders' equity$4,361,598 $8,608,151 
Impact of adjustment to exclude net unrealized gains or losses on fixed maturities1,707,588 (2,791,925)
Shareholders' equity, excluding net unrealized gains or losses on fixed maturities$6,069,186 $5,816,226 
Book value per share$44.56 $84.52 
Impact of adjustment to exclude net unrealized gains or losses on fixed maturities17.45 (27.41)
Book value per share, excluding net unrealized gains or losses on fixed maturities$62.01 $57.11 
(1) Calculated using average shareholders' equity for the measurement period.

INSURANCE OPERATIONS:

Life insurance accounted for 72% of the Company’s insurance underwriting margin for the quarter and 70% of total premium revenue.

Health insurance accounted for 28% of the Company's insurance underwriting margin for the quarter and 30% of total premium revenue.

Net sales of life insurance decreased 1% for the quarter and net health sales increased 10%.

The following table summarizes Globe Life's premium revenue by product type for the three months ended September 30, 2022 and 2021:
Insurance Premium Revenue
Quarter Ended
September 30, 2022September 30, 2021%
Chg.
Life insurance$755,115 $728,924 4
Health insurance319,289 299,143 7
Annuity— 
Total$1,074,405 $1,028,067 5
3
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
INSURANCE UNDERWRITING INCOME

Insurance underwriting margin is management’s measure of profitability of the Company's life, health, and annuity segments’ underwriting performance, and consists of premiums less policy obligations, commissions and other acquisition expenses. Insurance underwriting income is the sum of the insurance underwriting margins of the life, health, and annuity segments, plus other income, less insurance administrative expenses. It excludes the investment segment, Parent Company expense, stock compensation expense and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of underwriting results by distribution channel. Insurance underwriting income, a non-GAAP measure, is a component of net operating income, which is reconciled to net income in the Results of Operations section above.

The following table summarizes Globe Life's insurance underwriting income by segment for the three months ended September 30, 2022 and 2021:
Insurance Underwriting Income
Quarter Ended
September 30, 2022% of
Premium
September 30, 2021% of
Premium
%
Chg.
Insurance underwriting margins:
Life$208,155 28$161,994 2228
Health80,228 2576,978 264
Annuity2,070 2,178 
290,453 241,150 20
Other income398 321 
Administrative expenses(75,048)(68,036)10
Insurance underwriting income$215,803 $173,435 24
Per share$2.20 $1.69 30

The ratio of administrative expenses to premium was 7.0%, compared with 6.6% for the year-ago quarter.

4
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
LIFE INSURANCE RESULTS BY DISTRIBUTION CHANNEL

Our distribution channels consist of the following exclusive agencies: American Income Life Division (American Income), Liberty National Division (Liberty National) and Family Heritage Division (Family Heritage); an independent agency, United American Division (United American); and our Direct to Consumer Division.

Total premium, underwriting margins, first-year collected premium and net sales by all distribution channels are shown at https://investors.globelifeinsurance.com at "Financial Reports and Other Financial Information."
Life Underwriting Margin
Quarter Ended
September 30,
20222021
Amount% of PremiumAmount% of Premium% Chg.
American Income $128,389 34 $111,139 31 16
Direct to Consumer 38,520 16 12,083 219
Liberty National 18,858 23 16,173 21 17
Other 22,388 43 22,599 42 (1)
Total$208,155 28 $161,994 22 28
Life Premium
Quarter Ended
September 30,
20222021%
Chg.
American Income $378,306 $356,456 6
Direct to Consumer 242,550 240,578 1
Liberty National 82,072 78,528 5
Other 52,187 53,362 (2)
Total$755,115 $728,924 4
Life Net Sales(1)
Quarter Ended
September 30,
20222021%
Chg.
American Income $76,405 $73,649 4
Direct to Consumer 28,774 33,069 (13)
Liberty National 18,513 18,209 2
Other 2,321 2,726 (15)
Total$126,013 $127,653 (1)
(1)Net sales, a statistical performance measure, is calculated as annualized premium issued, net of cancellations in the first thirty days after issue, except in the case of Direct to Consumer, where net sales is annualized premium issued at the time the first full premium is paid after any introductory offer period has expired. Management considers net sales to be a better indicator of the rate of premium growth than annualized premium issued.

5
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
HEALTH INSURANCE RESULTS BY DISTRIBUTION CHANNEL
Health Underwriting Margin
Quarter Ended
September 30,
20222021
Amount% of PremiumAmount% of Premium% Chg.
United American $19,600 15 $17,524 15 12
Family Heritage 24,588 27 24,407 28 1
Liberty National 15,787 34 15,035 32 5
American Income 17,630 59 17,249 59 2
Direct to Consumer2,623 15 2,763 15 (5)
Total$80,228 25 $76,978 26 4
Health Premium
Quarter Ended
September 30,
20222021%
Chg.
United American $134,200 $118,240 13
Family Heritage 92,131 86,925 6
Liberty National 45,809 46,716 (2)
American Income 29,694 29,070 2
Direct to Consumer 17,455 18,192 (4)
Total$319,289 $299,143 7
Health Net Sales(1)
Quarter Ended
September 30,
20222021%
Chg.
United American $13,144 $11,849 11
Family Heritage 22,090 19,367 14
Liberty National 7,267 6,890 5
American Income 4,206 4,500 (7)
Direct to Consumer 574 481 19
Total$47,281 $43,087 10
(1)Net sales, a statistical performance measure, is calculated as annualized premium issued, net of cancellations in the first thirty days after issue, except in the case of Direct to Consumer, where net sales is annualized premium issued at the time the first full premium is paid after any introductory offer period has expired. Management considers net sales to be a better indicator of the rate of premium growth than annualized premium issued.

6
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
PRODUCING EXCLUSIVE AGENT COUNT RESULTS BY DISTRIBUTION CHANNEL

Quarterly Average
Producing Agent Count(1)
End of Quarter
 Agent Count
Quarter EndedQuarter Ended
September 30,June 30,September 30,June 30,
20222021% Chg.202220222021% Chg.2022
American Income9,477 9,959 (5)9,670 9,441 9,800 (4)9,637 
Liberty National 2,784 2,706 2,713 2,852 2,700 2,782 
Family Heritage 1,233 1,152 1,173 1,302 1,192 1,201 

(1) The quarterly average producing agent count is based on the actual count at the end of each week during the period.


INVESTMENTS

Management uses excess investment income as the measure to evaluate the performance of the investment segment. It is defined as net investment income less both the required interest attributable to net policy liabilities and the interest on debt. We also view excess investment income per diluted common share as an important and useful measure to evaluate performance of the investment segment, since it takes into consideration our stock repurchase program.

The following table summarizes Globe Life's investment income, excess investment income, and excess investment income per diluted common share.
Excess Investment Income
Quarter Ended
September 30,
20222021%
Chg.
Net investment income$245,625 $238,975 3
Required interest:
Interest on net policy liabilities(1)
(165,233)(158,855)4
Interest on debt(23,965)(20,886)15
Total required interest(189,198)(179,741)5
Excess investment income$56,427 $59,234 (5)
Per share$0.57 $0.58 (2)
(1)Interest on net policy liabilities is a component of total policyholder benefits, a GAAP measure.

Net investment income increased 2.8%, and average invested assets increased 4.1%. Required interest on net policy liabilities increased 4.0%, and average net policy liabilities increased 3.8%. The weighted average discount rate for the net policy liabilities was 5.8% and was in line with the year-ago quarter.

7
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
The composition of the investment portfolio at book value at September 30, 2022 is as follows:
Investment Portfolio
As of
September 30, 2022
Amount% of Total
Fixed maturities at fair value(1)
$16,005,140 91 
Policy loans605,426 
Other long-term investments(2)
907,390 
Short-term investments85,773 — 
Total$17,603,729 
(1) As of September 30, 2022, fixed maturities at amortized cost were $18.2 billion, net of $0 of allowance for credit losses.
(2) Includes $748 million of investments accounted for under the fair value option which have a cost of $731 million as of September 30, 2022.

Fixed maturities at amortized cost, net of allowance for credit losses, by asset class as of September 30, 2022 are as follows:
Fixed Maturity Portfolio by Sector
As of
September 30, 2022
Investment GradeBelow Investment GradeTotal Amortized Cost, net
Corporate bonds$14,375,378 $493,940 $14,869,318 
Municipals2,739,017 — 2,739,017 
Government, agencies and GSEs439,501 — 439,501 
Collateralized debt obligations— 36,721 36,721 
Other asset-backed securities76,207 12,707 88,914 
Total$17,630,103 $543,368 $18,173,471 

Below are fixed maturities available for sale by amortized cost, allowance for credit losses, and fair value at September 30, 2022 and the corresponding amounts of net unrealized gains or losses recognized in accumulated other comprehensive income (loss).
As of
Amortized
Cost
Allowance for Credit LossesNet Unrealized Gains (Losses)Fair
 Value
September 30, 2022
$18,173,471 $— $(2,168,331)$16,005,140 

At amortized cost, net of allowance for credit losses, 97% of fixed maturities (97% at fair value) were rated “investment grade.” The fixed maturity portfolio earned an annual taxable equivalent effective yield of 5.17% during the third quarter of 2022, compared with 5.21% in the year-ago quarter.

Globe Life is not a party to any credit default swaps and does not participate in securities lending.


8
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
Comparable information for acquisitions of fixed maturity investments is as follows:
Fixed Maturity Acquisitions
Quarter Ended
September 30,
20222021
Amount$430,578 $325,255 
Average annual effective yield5.6 %3.2 %
Average ratingAA+
Average life (in years) to:
Next call11.9 19.3 
Maturity17.7 29.2 

SHARE REPURCHASE:

During the quarter, the Company repurchased 563,574 shares of Globe Life Inc. common stock at a total cost of $56 million and an average share price of $99.43.

LIQUIDITY/CAPITAL:

Globe Life's operations consist primarily of writing basic protection life and supplemental health insurance policies which generate strong and stable cash flows. These cash flows are not impacted by volatile equity markets. Liquidity at the Parent Company is sufficient to meet additional capital needs of the insurance companies.

EARNINGS GUIDANCE FOR THE YEAR ENDING DECEMBER 31, 2022 and 2023:

Globe Life projects that net operating income per share will be in the range of $8.00 to $8.20 for the year ending December 31, 2022. For the year ending December 31, 2023, we estimate that net operating income per share, computed under current accounting guidance, will be in the range of $9.00 to $9.70. In addition, we estimate that the adoption of the new accounting guidance relating to long-duration life insurance contracts effective January 1, 2023 will provide an additional net increase in net operating income in the range of $105 million to $130 million, net of tax, primarily as a result of lower amortization of deferred acquisition costs.

NON-GAAP MEASURES:

In this news release, Globe Life includes non-GAAP measures to enhance investors' understanding of management's view of the business. The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing broader perspective. Globe Life's definitions of non-GAAP measures may differ from other companies' definitions. More detailed financial information, including various GAAP and non-GAAP measurements, is located at https://investors.globelifeinsurance.com on the Investors page under “Financial Reports and Other Financial Information."


9
GL Q3 2022 Earnings Release


CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This press release may contain forward-looking statements within the meaning of the federal securities laws, including statements related to the expected impact of the COVID-19 outbreak on our business operations, financial results and financial condition. These prospective statements reflect management’s current expectations, but are not guarantees of future performance. Whether or not actual results differ materially from forward-looking statements may depend on numerous foreseeable and unforeseeable events or developments, which may be national in scope, related to the insurance industry generally, or applicable to the Company specifically. Such events or developments could include, but are not necessarily limited to:

1) Economic and other conditions, including the COVID-19 pandemic and its impact on the U.S. economy, leading to unexpected changes in lapse rates and/or sales of our policies, as well as levels of mortality, morbidity, and utilization of health care services that differ from Globe Life's assumptions;

2) Regulatory developments, including changes in accounting standards or governmental regulations (particularly those impacting taxes and changes to the Federal Medicare program that would affect Medicare Supplement);

3) Market trends in the senior-aged health care industry that provide alternatives to traditional Medicare (such as Health Maintenance Organizations and other managed care or private plans) and that could affect the sales of traditional Medicare Supplement insurance;

4) Interest rate changes that affect product sales and/or investment portfolio yield;

5) General economic, industry sector or individual debt issuers’ financial conditions (including developments and volatility arising from the COVID-19 pandemic, particularly in certain industries that may comprise part of our investment portfolio) that may affect the current market value of securities we own, or that may impair an issuer’s ability to make principal and/or interest payments due on those securities;

6) Changes in pricing competition;

7) Litigation results;

8) Levels of administrative and operational efficiencies that differ from our assumptions (including any reduction in efficiencies resulting from increased costs arising from operating during the COVID-19 pandemic);

9) The ability to obtain timely and appropriate premium rate increases for health insurance policies from our regulators;

10) The customer response to new products and marketing initiatives;

11) Reported amounts in the consolidated financial statements which are based on management estimates and judgments which may differ from the actual amounts ultimately realized;

12) Compromise by a malicious actor or other event that causes a loss of secure data from, or inaccessibility to, our computer and other information technology systems;

13) The severity, magnitude and impact of the COVID-19 pandemic, including effects of the pandemic and the effects of the U.S. government’s and other businesses’ response to the pandemic, on our operations and personnel, and on commercial activity and demand for our products; and

14) Globe Life’s ability to access the commercial paper and debt markets, particularly if such markets become unpredictable or unstable for a certain period as a result of the COVID-19 pandemic.

Readers are also directed to consider other risks and uncertainties described in other documents on file with the Securities and Exchange Commission. Globe Life specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.
10
GL Q3 2022 Earnings Release


EARNINGS RELEASE CONFERENCE CALL WEBCAST:

Globe Life will provide a live audio webcast of its third quarter 2022 earnings release conference call with financial analysts at 11:00 am (Eastern) tomorrow, October 27, 2022. Access to the live webcast and replay will be available at https://investors.globelifeinsurance.com on the Calls and Meetings page, at the Conference Calls on the Web icon. Immediately following this press release, supplemental financial reports will be available before the conference call on the Investors page menu of the Globe Life website at “Financial Reports.”
For additional information contact:
Mike Majors, Executive Vice PresidentAdministration and Investor Relations
Globe Life Inc.
3700 South Stonebridge Drive
P. O. Box 8080
McKinney, Texas 75070-8080
Phone: 972-569-3627 or email: investors@globe.life
Website: https://investors.globelifeinsurance.com

11
GL Q3 2022 Earnings Release

GLOBE LIFE INC.
Earnings Release—Q3 2022
(Dollar amounts in thousands, except share and per share data)
(Unaudited)
APPENDIX

GLOBE LIFE INC.
GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended
September 30,
Nine Months Ended
September 30,
 2022202120222021
Revenue:
Life premium$755,115 $728,924 $2,269,641 $2,165,213 
Health premium319,289 299,143 955,478 888,902 
Other premium— 
Total premium1,074,405 1,028,067 3,225,120 3,054,116 
Net investment income245,625 238,975 733,101 713,103 
Realized gains (losses)(29,155)10,475 (66,845)47,286 
Other income398 321 861 1,004 
Total revenue1,291,273 1,277,838 3,892,237 3,815,509 
Benefits and expenses:
Life policyholder benefits494,627 516,196 1,555,004 1,532,298 
Health policyholder benefits198,415 187,906 592,488 564,589 
Other policyholder benefits6,986 7,303 21,110 21,848 
Total policyholder benefits700,028 711,405 2,168,602 2,118,735 
Amortization of deferred acquisition costs156,129 151,593 469,718 452,607 
Commissions, premium taxes, and non-deferred acquisition costs93,028 82,774 277,436 244,752 
Other operating expense88,140 80,385 262,150 240,750 
Interest expense23,965 20,886 65,737 63,833 
Total benefits and expenses1,061,290 1,047,043 3,243,643 3,120,677 
Income before income taxes229,983 230,795 648,594 694,832 
Income tax benefit (expense)(43,204)(41,924)(120,450)(127,826)
Net income$186,779 $188,871 $528,144 $567,006 
Total basic net income per common share$1.92 $1.86 $5.38 $5.53 
Total diluted net income per common share$1.90 $1.84 $5.33 $5.46 

12
GL Q3 2022 Earnings Release
EX-101.SCH 3 gl-20221026.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gl-20221026_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 gl-20221026_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Listings [Line Items] Entity Listings [Line Items] Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number 4.250% Junior Subordinated Debentures Subordinated Debt [Member] Written Communications Written Communications Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Local Phone Number Local Phone Number Cover page. Cover [Abstract] Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Listings [Table] Entity Listings [Table] Amendment Flag Amendment Flag Common Stock, $1.00 par value per share Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Class of Stock [Domain] Class of Stock [Domain] Document Type Document Type Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 6 gl-20221026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 globelifeheader.gif begin 644 globelifeheader.gif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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover page
Oct. 26, 2022
Entity Listings [Line Items]  
Document Type 8-K
Document Period End Date Oct. 26, 2022
Entity Registrant Name GLOBE LIFE INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-08052
Entity Tax Identification Number 63-0780404
Entity Address, Address Line One 3700 South Stonebridge Drive
Entity Address, City or Town McKinney
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75070
City Area Code 972
Local Phone Number 569-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000320335
Amendment Flag false
Common Stock, $1.00 par value per share  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $1.00 par value per share
Trading Symbol GL
Security Exchange Name NYSE
4.250% Junior Subordinated Debentures  
Entity Listings [Line Items]  
Title of 12(b) Security 4.250% Junior Subordinated Debentures
Trading Symbol GL PRD
Security Exchange Name NYSE
XML 9 gl-20221026_htm.xml IDEA: XBRL DOCUMENT 0000320335 2022-10-26 2022-10-26 0000320335 us-gaap:CommonStockMember 2022-10-26 2022-10-26 0000320335 us-gaap:SubordinatedDebtMember 2022-10-26 2022-10-26 0000320335 false 8-K 2022-10-26 GLOBE LIFE INC. DE 001-08052 63-0780404 3700 South Stonebridge Drive McKinney TX 75070 972 569-4000 false false false false Common Stock, $1.00 par value per share GL NYSE 4.250% Junior Subordinated Debentures GL PRD NYSE false 2022-10-26 2022-10-26 EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 3 22 1 false 2 0 false 0 false false R1.htm 0001001 - Document - Cover page Sheet http://www.globelifeinsurance.com/role/Coverpage Cover page Cover 1 false false All Reports Book All Reports gl-20221026.htm gl-20221026.xsd gl-20221026_def.xml gl-20221026_lab.xml gl-20221026_pre.xml q3fy2022earningsrelease.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gl-20221026.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "gl-20221026_def.xml" ] }, "inline": { "local": [ "gl-20221026.htm" ] }, "labelLink": { "local": [ "gl-20221026_lab.xml" ] }, "presentationLink": { "local": [ "gl-20221026_pre.xml" ] }, "schema": { "local": [ "gl-20221026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 2, "nsprefix": "gl", "nsuri": "http://www.globelifeinsurance.com/20221026", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gl-20221026.htm", "contextRef": "ifa166b6af44148e6828994de9acf3d6e_D20221026-20221026", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover page", "role": "http://www.globelifeinsurance.com/role/Coverpage", "shortName": "Cover page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gl-20221026.htm", "contextRef": "ifa166b6af44148e6828994de9acf3d6e_D20221026-20221026", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]", "terseLabel": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]", "terseLabel": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock, $1.00 par value per share" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "stringItemType" }, "us-gaap_SubordinatedDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Debt [Member]", "terseLabel": "4.250% Junior Subordinated Debentures" } } }, "localname": "SubordinatedDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.globelifeinsurance.com/role/Coverpage" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0000320335-22-000028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000320335-22-000028-xbrl.zip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